No Data
No Data
When Will Theralase Technologies Inc. (CVE:TLT) Become Profitable?
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
Theralase Technologies Inc. (TLTFF) Q2 2024 Earnings Call Transcript Summary
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
No Data